Analysts expect Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) to report sales of $6.24 million for the current quarter, according to Zacks Investment Research. Two analysts released earnings estimates for Sensus Healthcare. The lowest sales estimate is $5.22 million and the highest is $7.25 million. Sensus Healthcare recorded sales of $3.07 million in the same quarter last year, indicating a positive year-over-year growth rate of 103.3%. The company is expected to release its next results after the market closes on Monday, January 1.
According to Zacks, analysts expect Sensus Healthcare to report annual revenue of $32.12 million for the current fiscal year, with estimates ranging from $31.57 million to $32.66 million. of dollars. For the next fiscal year, analysts expect the company to post sales of $36.61 million. Zacks sales averages are an average average based on a survey of sell-side research companies that cover Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS – Get Rating) last released its quarterly earnings data on Thursday, February 10. The company reported earnings per share of $0.32 for the quarter, beating the Zacks consensus estimate of $0.14 by $0.18. Sensus Healthcare achieved a net margin of 15.23% and a return on equity of 18.88%. The company posted revenue of $13.03 million in the quarter, compared to $11.01 million expected by analysts. During the same period last year, the company posted EPS of $0.06.
SRTS has been the subject of several reports by research analysts. HC Wainwright raised its target price on Sensus Healthcare shares from $12.00 to $13.00 and gave the stock a “buy” rating in a Thursday, March 3 research report. TheStreet upgraded Sensus Healthcare from a ‘c’ rating to a ‘b-‘ rating in a Friday, February 11 report. Finally, Maxim Group assumed coverage of Sensus Healthcare in a Friday, February 11 report. They set a “buy” rating and a price target of $12.00 on the stock.
Separately, CEO Joseph C. Sardano sold 44,782 shares of the company in a trade on Friday, March 11. The stock was sold at an average price of $10.11, for a total transaction of $452,746.02. The sale was disclosed in a document filed with the SEC, accessible via this link. Additionally, CFO Javier Rampolla sold 9,000 shares of the company in a trade on Friday, March 4. The stock was sold at an average price of $9.42, for a total value of $84,780.00. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 114,056 shares of the company worth $1,151,818. 24.30% of the shares are currently held by insiders of the company.
Several large investors have recently changed their positions in the company. Marshall Wace LLP purchased a new stake in Sensus Healthcare in Q4 worth approximately $1,413,000. Renaissance Technologies LLC increased its stake in Sensus Healthcare by 634.9% during the fourth quarter. Renaissance Technologies LLC now owns 161,934 shares of the company worth $1,169,000 after acquiring an additional 139,900 shares during the period. Acadian Asset Management LLC purchased a new stake in Sensus Healthcare stock during Q4 for $791,000. Cubist Systematic Strategies LLC purchased a new stake in Sensus Healthcare stock during Q4 for $281,000. Finally, Morgan Stanley increased its stake in shares of Sensus Healthcare by 340.4% during the 1st quarter. Morgan Stanley now owns 44,894 shares of the company worth $172,000 after purchasing an additional 34,699 shares during the period. 14.64% of the shares are currently held by institutional investors.
NASDAQ:SRTS opened at $7.30 on Friday. The company has a market capitalization of $121.60 million, a price-earnings ratio of 30.42 and a beta of 0.30. The company’s fifty-day simple moving average is $9.98 and its 200-day simple moving average is $7.69. Sensus Healthcare has a 12-month low of $3.08 and a 12-month high of $11.96.
Company Profile Sensus Health (Get a rating)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a low-energy superficial x-ray radiation therapy system that offers patients an alternative to surgery for the treatment of non-melanoma skin cancers, including basal cell and squamous cell cancers, as well as other cancers. other skin conditions, such as keloids. ; and SRT-100 Vision, which provides the user with an SRT-friendly treatment planning application that integrates the built-in high-frequency ultrasound imaging module, volumetric tumor analysis, beam margin planning and dosimetry parameters.
Get a Free Copy of Zacks’ Research Report on Sensus Healthcare (SRTS)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Sensus Healthcare Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Sensus Healthcare and related companies with MarketBeat.com’s free daily email newsletter.